Kaposi's Sarcoma

Kaposi's Sarcoma (KS) is a complex neoplastic disorder characterized by the proliferation of angiogenic tumours, primarily affecting the skin but also involving mucous membranes, lymph nodes, and visceral organs. Despite its rarity, KS has garnered attention due to its association with immunocompromised states, particularly HIV/AIDS.  

---

What Causes Kaposi's Sarcoma?

Kaposi's Sarcoma is induced by the human herpesvirus 8 (HHV-8), also known as Kaposi's Sarcoma-associated herpesvirus (KSHV). The viral pathogen is considered necessary but not sufficient to cause KS, implying that additional co-factors, such as immunosuppression or genetic predisposition, contribute to disease manifestation.

Viral Pathogenesis

HHV-8 is a gamma-herpesvirus that establishes latency in endothelial cells, B lymphocytes, and monocytes. It encodes several oncogenic proteins that dysregulate cellular pathways, promoting angiogenesis and cellular proliferation, hallmark features of Kaposi's Sarcoma.

---

Types of Kaposi's Sarcoma

Kaposi's Sarcoma presents in four distinct epidemiological forms, each with unique clinical and demographic characteristics.

Classic Kaposi's Sarcoma

Classic KS predominantly affects elderly Mediterranean or Eastern European men. It exhibits an indolent course with lesions primarily localized to the lower extremities.

Endemic (African) Kaposi's Sarcoma

Endemic KS is prevalent in sub-Saharan Africa, where it occurs in both children and adults. This form is more aggressive than classic KS and often involves lymph nodes.

Iatrogenic (Transplant-Associated) Kaposi's Sarcoma

Iatrogenic KS arises in individuals undergoing immunosuppressive therapy, particularly organ transplant recipients. Reduction of immunosuppression can lead to lesion regression.

Epidemic (AIDS-Associated) Kaposi's Sarcoma

Epidemic KS is linked with HIV/AIDS and is the most aggressive form, often disseminating to visceral organs. The advent of antiretroviral therapy has significantly reduced its incidence.

---

Symptoms of Kaposi's Sarcoma

Vascular lesions with varying clinical presentations characterize Kaposi's Sarcoma, contingent upon the affected anatomical site.

Cutaneous Manifestations

KS lesions are typically violaceous macules, plaques, or nodules that may coalesce. If they ulcerate or involve sensitive areas, they can cause significant morbidity.

Visceral Involvement

In advanced cases, KS can affect visceral organs, leading to gastrointestinal bleeding, respiratory distress, or lymphatic obstruction, necessitating prompt medical intervention.

---

Risk Factors for Kaposi's Sarcoma

Several risk factors predispose individuals to Kaposi's Sarcoma, reflecting the interplay between viral infection and host susceptibility.

Immunosuppression

Immunocompromised states, such as HIV infection or post-transplant immunosuppression, significantly elevate KS risk due to impaired immune surveillance against HHV-8.

Genetic Predisposition

Genetic factors may influence susceptibility to HHV-8 infection and KS development, although specific genetic markers remain under investigation.

Demographic Factors

Specific populations, including men of Mediterranean or Eastern European descent and individuals in sub-Saharan Africa, exhibit higher KS prevalence.

---

Diagnosing Kaposi's Sarcoma

The diagnosis of Kaposi's Sarcoma is primarily clinical, supported by histopathological and molecular techniques.

Clinical Examination

A thorough dermatological examination often reveals characteristic lesions. Dermoscopy can aid in differentiating KS from other vascular lesions.

Histopathology

Biopsy of suspected lesions is essential for confirming KS diagnosis. Histological examination reveals spindle cell proliferation, slit-like vascular spaces, and hemosiderin deposition.

Molecular Diagnostics

Polymerase chain reaction (PCR) can detect HHV-8 DNA in lesional tissue, supporting the diagnosis, particularly in atypical presentations.

---

Treatment Modalities for Kaposi's Sarcoma

The therapeutic approach to Kaposi's Sarcoma is multifaceted and tailored to the disease severity, location, and immunological status of the patient.

Antiretroviral Therapy

Antiretroviral therapy (ART) is paramount for epidemic KS. Effective ART can lead to immune reconstitution, reducing KS lesion burden and progression.

Chemotherapy

Systemic chemotherapy, including liposomal anthracyclines and taxanes, is indicated for advanced or rapidly progressing KS. These agents target proliferating spindle cells, reducing lesion size and symptoms.

Immunomodulatory Agents

Interferon-alpha has demonstrated efficacy in certain KS cases, particularly in those with preserved immune function. It enhances immune-mediated tumour clearance.

Surgical and Local Therapies

Localized treatments, such as cryotherapy, laser therapy, or surgical excision, may be employed for isolated lesions, providing symptomatic relief and cosmetic improvement.